Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms

Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms

Dosimetry during peptide receptor radionuclide therapy (PRRT) has mainly focused on normal organs and less on the tumors. The absorbed dose in one target tumor per patient and several response related factors were assessed in 23 pancreatic neuroendocrine neoplasms (P-NENs) and 25 small-intestinal NE...

Full description

Bibliographic Details
Main Authors: Ulrika Jahn, Ezgi Ilan, Mattias Sandström, Mark Lubberink, Ulrike Garske-Román, Anders Sundin
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
radionuclide therapy
theranostics
<sup>177</sup>Lu-DOTATATE
PRRT
small intestinal NEN
pancreatic NEN
Online Access:https://www.mdpi.com/2072-6694/13/5/962

Similar Items

Similar Items